Supplementary Table S2. Echocardiographic Characteristics of HIV-Exposed Uninfected Children Born to HIV-Infected Mothers and Exposed *In Utero* to Zidovudine Monotherapy or Combination Antiretroviral Therapy

| Echocardiographic Z-score | Unadjusted Z-score mean (SE) | | | Adjusted ^a Z-score mean (SE) | | |
|--|------------------------------|------------------------------------|------|---|------------------------------------|------|
| | Monotherapy (n=58) | Exposed to combination ARVs (n=98) | P | Monotherapy (n=58) | Exposed to combination ARVs (n=98) | P |
| Functional systolic parameters | | | | | | |
| Contractility | 0.31 (0.14) | 0.35 (0.11) | .83 | 0.32 (0.20) | 0.34 (0.14) | .95 |
| Fractional shortening | 0.42(0.12) | 0.36(0.10) | .70 | 0.50(0.18) | 0.31(0.12) | .45 |
| Ejection fraction | 0.16 (0.12) | 0.18 (0.09) | .88 | 0.34 (0.17) | 0.08 (0.12) | .29 |
| Functional diastolic parameters | | | | | | |
| Peak early velocity | 0.27(0.13) | 0.42(0.10) | .34 | 0.33 (0.18) | 0.38(0.12) | .83 |
| Peak atrial velocity | 0.29 (0.18) | 0.30 (0.14) | .97 | 0.41 (0.25) | 0.23 (0.17) | .63 |
| Peak early/atrial velocity (E/A ratio) | -0.07(0.13) | 0.07 (0.10) | .39 | -0.15(0.19) | 0.11 (0.13) | .34 |
| Peak early tissue (E') | 0.48 (0.22) | 0.39 (0.16) | .74 | 0.80 (0.30) | 0.19 (0.20) | .15 |
| Peak early inflow/early tissue (E/E') | -0.12(0.20) | 0.18(0.15) | .22 | -0.36(0.27) | 0.32 (0.18) | .087 |
| Peak early deceleration time | -0.17(0.14) | -0.43(0.10) | .14 | 0.10 (0.20) | -0.59 (0.13) | .016 |
| Structural parameters | | | | | | |
| LV mass | 0.03 (0.12) | 0.11 (0.09) | .55 | -0.11(0.16) | 0.20(0.11) | .19 |
| ED LV volume | -0.16(0.13) | -0.19(0.10) | .86 | -0.05(0.18) | -0.24(0.12) | .45 |
| ES LV volume | -0.45(0.14) | -0.11 (0.10) | .047 | -0.29 (0.16) | -0.19 (0.11) | .67 |
| Mass-to-volume ratio | 0.31 (0.13) | 0.24 (0.10) | .68 | -0.08(0.16) | 0.46 (0.11) | .024 |

Results of linear regression modeling, excluding those unexposed to any ARVs during pregnancy (n = 18). Each row represents a separate linear regression model comparing youth exposed to zidovudine monotherapy with those exposed to two or more ARVs.

^aAdjusted for age, sex, race/ethnicity, BMI Z-score, and SBP Z-score; diastolic function measures also adjusted for heart rate. ARVs, antiretrovirals; D, diastolic; S, systolic; BMI, body-mass index; SBP, systolic blood pressure.